Meet The Team
Dori Thomas-Karyat, PhD
Founder and CEO
Dori has 20+ years of experience in the immuno-oncology space. She is an expert in the field of TGF-ß. Prior to founding Synthis Therapeutics, Dori worked in pharma drug discovery at Abbvie and Roche as a project lead. She did her Post-doctoral Cancer Research Institute fellow at MSKCC. She received her immunology Ph.D. from Washington University in St. Louis.
Bob Lutz, PhD
Chief Development Officer
Dr. Lutz has 30+ years of biotech experience and is an expert in ADC discovery through clinical development. Previously he worked at Immunogen as the Vice President of Translational Research and Development. He has research in Kadcyla, the first FDA-approved ADC for solid tumor indication and coltuximab ravtansine, a CD19 targeting ADC for DLBCL. He was also the former CDO of Forbius, a TGFb company purchased by BMS in 2020.
Dr. Lutz received his BS and PhD in biochemistry from the University of New Hampshire and Brandeis University, respectively, and was a postdoctoral fellow at the Eleanor Roosevelt Institute.
Bill Tanner, PhD, MBA
Chief Financial Officer
Meet The Team
Dori Thomas-Karyat, PhD
Founder and CEO
Dr. Thomas-Karyat has 20+ years of experience in the immuno-oncology space and is a TGF-ß expert. Prior to founding Synthis Therapeutics, she worked in pharma as a drug discovery project lead at both Abbvie and Roche, in the depts of Cancer Immuno-oncology and Inflammation. She did her Post-doctoral fellowship at Memoral Sloan Kettering Cancer Center, in the lab of Dr. Joan Massague, head of Sloan Kettering Research Institute in New York and leader in the field of TGF-ß. As a postdoc, she was supported by Cancer Research Institute Fellowship. She received her Ph.D. in Immunology from Washington University in St. Louis School of Medicine.
Bob Lutz, PhD
Chief Development Officer
Dr. Lutz has 30+ years of biotech experience and is an expert in ADC discovery through clinical development. Previously he worked at Immunogen as the Vice President of Translational Research and Development. He has research in Kadcyla, the first FDA-approved ADC for solid tumor indication and coltuximab ravtansine, a CD19 targeting ADC for DLBCL. He was also the former CDO of Forbius, a TGFb company purchased by BMS in 2020.
Dr. Lutz received his BS and PhD in biochemistry from the University of New Hampshire and Brandeis University, respectively, and was a postdoctoral fellow at the Eleanor Roosevelt Institute.
.jpg)
Bill Tanner, PhD, MBA
Chief Financial Officer
Dr. Bill Tanner William (Bill) Tanner has more than 25 years of experience in life science corporate development, capital raising and investment banking. He most recently served as Co-founder and CFO of ImmunoGenesis, a clinical stage immuno-oncology company. He previously spent 20 years as a biotech and biopharma research analyst for leading healthcare investment banks including SG Cowen, Leerink Swann, Lazard Capital Markets, Guggenheim Securities and Vector Securities International. He has been involved in raising billions of dollars for public and private life science companies. Bill holds a PhD in physiology from Texas A&M University and completed post-doctoral training at the Washington University School of Medicine Center for Immunology and an MBA from the Olin School of Business at Washington University